India's Mankind Pharmaceuticals intends to take on the nation's giant drugmakers by spending more than $80 million acquiring local pharmas in niche markets, its managing director said in an interview. It also seeks licensing deals with multinationals, he said.
Suven Life Sciences is betting $25 million on U.S. clinical trials for its SUVN-502 as a necessary step to attract other companies to license the drug based on a molecule for treating Alzheimer's disease.
Six years after Catalyst Biosciences inked a $500 million-plus deal to develop Factor VIIa therapies for hemophilia, Pfizer is walking away from the pact it inherited from Wyeth. And now Targacept, which just struck a reverse merger pact to get Catalyst on to the public market, is considering the implications for their tie-up after the biotech's stock took a nasty dive as news of the breakup spread.
CRO giant Parexel International has unveiled three new education programs in partnership with schools around the world, lending its expertise in hopes of training the next generation of clinical researchers.
The operators of a pair of private hospital networks, one in Japan and the other in South Korea, signed a memorandum of understanding to cooperate on research into regenerative medicine, the work ranging from education activities to clinical applications.
PPD and partner Shin Nippon Biomedical Laboratories have hit the ground running with their Japanese joint venture, closing a deal that will see them join forces in the country's growing market for clinical trials.
Australia's Phylogica signed an equity stake licensing agreement with U.K.-based PhoreMost for the use of certain Phylomer libraries solely for phenotypic screening to identify novel targets for diseases such as cancer and develop small molecule drugs.
Dr. Reddy's Laboratories has licensed the Generx gene-therapy heart drug now in Phase III trials from U.S.-based Taxus Cardium Pharmaceuticals Group for the Myanmar, Russia, Vietnam and other markets. Financial arrangements for the deal were not disclosed.
Shares of Regulus spiked 10% Tuesday afternoon after its Big Pharma partner AstraZeneca stepped up to grab rights to a preclinical drug candidate for NASH with plans to steer it into clinical studies.
VBI Vaccines announced Monday that it is collaborating with Sanofi's vaccines unit to apply its Lipid Particle Vaccine to improve the stability of an undisclosed Sanofi Pasteur candidate. The terms of the agreement were not disclosed.